They reported their findings in the latest issue of the British Journal of Cancer.
The population-based case-control study was conducted in five Swedish counties. A total of 567 incident cases of gastric cancer and 1,165 controls were interviewed about their use of pain relievers.
The cases were uniformly classified to subsite (cardia/non-cardia) and histological type. Information was also collected on other known risk factors for gastric cancer.
|Aspirin users were 30% less likely to have gastric cancer than non-users.|
|British Journal of Cancer|
Users of aspirin were found to have a moderately reduced risk of gastric cancer compared to those who never used the drug. The odds ratio adjusted for age, gender, and socioeconomic status was 0.7.
Gastric cancer risk fell with increasing frequency of aspirin use. The risk reduction was apparent for both cardia and non-cardia tumours, but was uncertain for the diffuse histologic type.
No clear association was observed between gastric cancer risk and non-aspirin NSAIDs or other studied pain relievers.
Resaercher K. Akre concluded on behalf of the group, "Our finding lends support to the hypothesis that use of aspirin reduces the risk for gastric cancer."